Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis

Lancet
Andrea CiprianiJohn R Geddes

Abstract

Major depressive disorder is one of the most common, burdensome, and costly psychiatric disorders worldwide in adults. Pharmacological and non-pharmacological treatments are available; however, because of inadequate resources, antidepressants are used more frequently than psychological interventions. Prescription of these agents should be informed by the best available evidence. Therefore, we aimed to update and expand our previous work to compare and rank antidepressants for the acute treatment of adults with unipolar major depressive disorder. We did a systematic review and network meta-analysis. We searched Cochrane Central Register of Controlled Trials, CINAHL, Embase, LILACS database, MEDLINE, MEDLINE In-Process, PsycINFO, the websites of regulatory agencies, and international registers for published and unpublished, double-blind, randomised controlled trials from their inception to Jan 8, 2016. We included placebo-controlled and head-to-head trials of 21 antidepressants used for the acute treatment of adults (≥18 years old and of both sexes) with major depressive disorder diagnosed according to standard operationalised criteria. We excluded quasi-randomised trials and trials that were incomplete or included 20% or more of...Continue Reading

Associated Datasets

Citations

Mar 27, 2018·Journal of Child Psychology and Psychiatry, and Allied Disciplines·Emily Simonoff
Jun 8, 2018·International Journal of Epidemiology·Georgia SalantiMatthias Egger
May 23, 2018·Psychotherapy and Psychosomatics·Steven L Dubovsky
Jun 29, 2018·The British Journal of Psychiatry : the Journal of Mental Science·Ymkje Anna de VriesPeter de Jonge
Jul 3, 2018·Psychological Medicine·Christian A WebbDiego A Pizzagalli
Jun 9, 2018·Drug and Therapeutics Bulletin
Jun 21, 2018·BMJ Evidence-based Medicine·Nav Persaud
Jul 31, 2018·The British Journal of Psychiatry : the Journal of Mental Science·Derek K TracySukhwinder S Shergill
Aug 19, 2018·Experimental Physiology·Christoffer van Tulleken
Sep 1, 2018·Journal of Psychosocial Nursing and Mental Health Services·Barbara J Limandri
Sep 11, 2018·Australasian Psychiatry : Bulletin of Royal Australian and New Zealand College of Psychiatrists·Nicholas A KeksDavid L Copolov
Sep 18, 2018·Expert Opinion on Drug Discovery·Mauro Giovanni CartaAntonio Preti
Oct 9, 2018·Journal of Psychopharmacology·Allan H Young
Oct 13, 2018·Acta Neuropsychiatrica·Konstantinos N Fountoulakis, Kyriakos Souliotis
Nov 21, 2018·The British Journal of Psychiatry : the Journal of Mental Science·Rebecca StrawbridgeAllan H Young
Aug 30, 2018·BMJ Evidence-based Medicine·Michael P Hengartner
Nov 21, 2018·Expert Opinion on Drug Discovery·Xenia GondaFrank I Tarazi
Dec 7, 2018·European Journal of Clinical Investigation·John P A Ioannidis
Dec 1, 2018·JAMA : the Journal of the American Medical Association·Pim Cuijpers
Dec 7, 2018·Journal of Medical Economics·Joran LokkerbolMickaël Hiligsmann
Jan 1, 2019·Expert Review of Respiratory Medicine·N LovellI J Higginson
Jan 3, 2019·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Jim van OsPhilippe Delespaul
Jan 8, 2019·Harvard Review of Psychiatry·Christoforos Iraklis Giakoumatos, David Osser
Jan 11, 2019·JCI Insight·Johannes M HenningsStefan Kloiber
Nov 6, 2018·International Journal of Mental Health Nursing·Timothy Wand
Jan 18, 2019·Movement Disorders : Official Journal of the Movement Disorder Society·Klaus SeppiUNKNOWN the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders So
Dec 26, 2018·Acta Psychiatrica Scandinavica·A Bayes, G Parker
Jan 31, 2019·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·Yu P Sivolap
Dec 12, 2018·International Clinical Psychopharmacology·Giovanni OstuzziCorrado Barbui
Feb 7, 2019·The New England Journal of Medicine·Lawrence T Park, Carlos A Zarate
Jan 31, 2019·Acta Psychiatrica Scandinavica·A BraillonF Naudet
Oct 4, 2018·Basic & Clinical Pharmacology & Toxicology·Giulio CastelpietraBjorn Wettermark
Jan 17, 2019·The International Journal of Neuropsychopharmacology·Ryosuke ArakawaJohan Lundberg
Feb 28, 2019·Journal of Psychopharmacology·Jonathan D HaffertyAndrew M McIntosh
Mar 1, 2019·The Australian and New Zealand Journal of Psychiatry·Bernhard T BauneGin S Malhi

❮ Previous
Next ❯

Software Mentioned

R
netmeta
Stata
OpenBUGS

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.